Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

Administered By

Awarded By

Contributors

Start/End

  • December 8, 2021 - September 17, 2026